1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Aldose Reductase

Aldose Reductase

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Aldose Reductase Related Products (35):

Cat. No. Product Name Effect Purity
  • HY-N0102
    Inhibitor 98.17%
    Isoliquiritigenin is an anti-tumor flavonoid from the root of Glycyrrhiza uralensis Fisch., which inhibits aldose reductase with an IC50 of 320 nM. Isoliquiritigenin is a potent inhibitor of influenza virus replication with an EC50 of 24.7 μM.
  • HY-66009
    Inhibitor 99.72%
    Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.
  • HY-105185
    Inhibitor 99.35%
    Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
  • HY-106697
    Inhibitor 99.71%
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol.
  • HY-16500
    Inhibitor 99.37%
    Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
  • HY-146129
    Aldose reductase-IN-5
    As an aldose reductase (ALR2) inhibitor, the compound is used to enhance the combination of inhibitory excitability and antioxidant capacity to delay the progress of diabetes complications.
  • HY-147977
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity.
  • HY-150630
    ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC50=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research.
  • HY-16255
    Inhibitor 99.86%
    Imirestat (AL 1576) is an aldose reductase inhibitor, used for the treatment of diabetes.
  • HY-N0310
    Soyasaponin Bb
    Inhibitor 99.13%
    soyasaponin Bb is a soyasaponin isolated from Phaseolus vulgaris, acting as an aldose reductase differential inhibitor (ARDI).
  • HY-15314
    Inhibitor 98.32%
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas.
  • HY-106198
    Inhibitor 99.50%
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation.
  • HY-18967
    Inhibitor 99.88%
    Caficrestat (Aldose reductase-IN-1) is a inhibitor of aldose reductase with IC50 of 28.9 pM.
  • HY-N0033
    Inhibitor 99.80%
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity.
  • HY-B1202
    Inhibitor 99.80%
    Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
  • HY-129586
    Inhibitor 99.33%
    AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.
  • HY-50289
    Inhibitor 99.85%
    Sorbinil, is an Aldose reductase inhibitor (ARI). Sorbinil plays therapeutic role in treating diabetes and diabetic complications, decreases AR activity and inhibits polyol pathway, it to be found comparatively safer than other ARIs for human use.
  • HY-19687
    Inhibitor 99.94%
    Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications.
  • HY-16433
    Inhibitor 98.09%
    Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.
  • HY-139696
    AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells.